XORTX Therapeutics Adjusts Warrant Exercise Price
XORTX Announces Publication of Key Research in ADPKD
CALGARY, Alberta, April 22, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ)), a late-stage clinical pharmaceutical company
XORTX Therapeutics Boosts Board With Biotech Pro
XORTX Therapeutics Appoints Industry Leader to Board
XORTX Announces Participation in Spring 2024 Investor Conferences
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ)), a late-stage clinical pharmaceutical company
Xortx Therapeutics Reports Stable Finances
XORTX Announces New Clinical Advisory Board Member
CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ)), a biopharmaceutical company focused on developing
XORTX: A Year of Milestones and Strategic Advancements as It Readies for a Registration Clinical Trial
XORTX Therapeutics Advances Kidney Disease Program
XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
CALGARY, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ)), a late-stage clinical pharmaceutical company
XORTX Therapeutics Announces Warrant Repricing
XORTX Reprices Warrants Issued in Connection With Previous Private Placements
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, March 11, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Compa
BeyondSpring, EnVVeno Medical, Aptorum Group Among Healthcare Movers
XORTX Therapeutics Completes Funding Round
XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, March 04, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Compan
XORTX Raises $2.5 Million Under Prospectus Supplement and Concurrent Private Placement for the Offering of Units
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Feb. 15, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company
XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Feb. 01, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company
XORTX Announces $2 Million Public Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Jan. 15, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company
Opko Health, LifeMD Among Healthcare Movers
Alliance Global Partners Maintains Buy on XORTX Therapeutics, Raises Price Target to $14
Alliance Global Partners analyst James Molloy maintains XORTX Therapeutics (NASDAQ:XRTX) with a Buy and raises the price target from $9 to $14.
No Data